Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gastric Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 31 articles: HTML format

Single Articles

October 2026
1. SHI CW, Singh A, Khosla AA, Thummalapalli R, et al
   Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.
   Eur J Cancer. 2026;246:117004.
   PubMed     Abstract available
   
   
   August 2026
2. RUHLE A, Krause A, O'Connell RL, Simes J, et al
   Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial.
   Eur J Cancer. 2026;246:117005.
   PubMed     Abstract available
   
   
   March 2026
3. LEITE LF, Noronha MM, Menezes S, Conceicao LDD, et al
   Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
   Eur J Cancer. 2026;237:116602.
   PubMed     Abstract available
   
   
   
4. ZAANAN A, Palle J, Renaud F, Barret M, et al
   Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP).
   Eur J Cancer. 2026;240:116697.
   PubMed     Abstract available
   
   
   January 2026
5. DOS SANTOS M, Lequesne J, Piessen G, Leconte A, et al
   Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
   Eur J Cancer. 2026;236:116258.
   PubMed     Abstract available
   
   
   
6. LEONE AG, Petrelli F, Klempner SJ, Smyth EC, et al
   Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis.
   Eur J Cancer. 2026;232:116155.
   PubMed     Abstract available
   
   
   December 2025
7. LOWERY MA, Wyrwicz LS, Oh DY, Shiu KK, et al
   First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
   Eur J Cancer. 2025;231:115807.
   PubMed     Abstract available
   
   
   
8. CRISTARELLA E, Ambrosini M, Di Maio M, Lonardi S, et al
   Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.
   Eur J Cancer. 2025;231:116060.
   PubMed     Abstract available
   
   
   November 2025
9. BAI C, Zheng Y, Sun M, Ying J, et al
   Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial.
   Eur J Cancer. 2025;230:115808.
   PubMed     Abstract available
   
   
   August 2025
10. VAN AMELSFOORT RM, Gonzalez P, Simoes R, Jansen EPM, et al
    A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.
    Eur J Cancer. 2025;228:115672.
    PubMed     Abstract available
    
    
    July 2025
11. GANAME S, Walter T, Durand A, Lievre A, et al
    Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.
    Eur J Cancer. 2025;225:115450.
    PubMed     Abstract available
    
    
    May 2025
12. ROSANU NM, Gervaso L, Cella CA, Fazio N, et al
    Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.
    Eur J Cancer. 2025;224:115521.
    PubMed     Abstract available
    
    
    March 2025
13. KAMP D, May AM, Adenis A, Capela A, et al
    Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study.
    Eur J Cancer. 2025;218:115278.
    PubMed     Abstract available
    
    
    
14. SATOH T, Barthelemy P, Nogova L, Honda K, et al
    Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
    Eur J Cancer. 2025;218:115262.
    PubMed     Abstract available
    
    
    February 2025
15. ISHIDA H, Sunakawa Y, Kodera Y, Yoshida K, et al
    Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.
    Eur J Cancer. 2025;219:115322.
    PubMed     Abstract available
    
    
    November 2024
16. GEERTS JFM, Pape M, Vissers PAJ, Verhoeven RHA, et al
    Patient access to perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with resectable gastric cancer in the Netherlands.
    Eur J Cancer. 2024;214:115137.
    PubMed     Abstract available
    
    
    October 2024
17. FUJITANI K, Kurokawa Y, Wada R, Takeno A, et al
    Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival.
    Eur J Cancer. 2024;213:115080.
    PubMed     Abstract available
    
    
    
18. SCHIRIZZI A, Donghia R, De Nunzio V, Renna N, et al
    High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma.
    Eur J Cancer. 2024;213:115066.
    PubMed     Abstract available
    
    
    June 2024
19. KROESE TE, Bronzwaer S, van Rossum PSN, Schoppman SF, et al
    European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
    Eur J Cancer. 2024;204:114062.
    PubMed     Abstract available
    
    
    May 2024
20. RAIMONDI A, Kim YW, Kang WK, Langley RE, et al
    Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
    Eur J Cancer. 2024;203:114043.
    PubMed     Abstract available
    
    
    April 2024
21. DIERKS S, Buchholz SM, Konig A, Liersch T, et al
    Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.
    Eur J Cancer. 2024;204:114076.
    PubMed    
    
    
    January 2024
22. ZHAO P, Li S, Du X
    Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer: A long way to go.
    Eur J Cancer. 2024;199:113554.
    PubMed    
    
    
    
23. VAN DER SLUIS K, Taylor SN, Kodach LL, van Dieren JM, et al
    Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.
    Eur J Cancer. 2024;199:113541.
    PubMed     Abstract available
    
    
    December 2023
24. TAIEB J, Bennouna J, Penault-Llorca F, Basile D, et al
    Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
    Eur J Cancer. 2023;195:113370.
    PubMed     Abstract available
    
    
    September 2023
25. AIX PONCE S, Cousin S, Dubos P, Belcaid L, et al
    Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
    Eur J Cancer. 2023;193:113309.
    PubMed    
    
    
    
26. MUTI HS, Rocken C, Behrens HM, Loffler CML, et al
    Deep learning trained on lymph node status predicts outcome from gastric cancer histopathology: a retrospective multicentric study.
    Eur J Cancer. 2023;194:113335.
    PubMed     Abstract available
    
    
    July 2023
27. KALFF MC, Dijksterhuis WPM, Wagner AD, Oertelt-Prigione S, et al
    Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
    Eur J Cancer. 2023;187:114-123.
    PubMed     Abstract available
    
    
    June 2023
28. ASPLUND JPU, Mackenzie HA, Markar SR, Lagergren JHF, et al
    Surgeon proficiency gain and survival after gastrectomy for gastric adenocarcinoma: A population-based cohort study.
    Eur J Cancer. 2023;186:91-97.
    PubMed     Abstract available
    
    
    
29. JIA K, Chen Y, Xie Y, Chong X, et al
    Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
    Eur J Cancer. 2023;189:112931.
    PubMed     Abstract available
    
    
    April 2023
30. PORTH I, Hirsch D, Ceribas Y, Weidner P, et al
    Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Eur J Cancer. 2023;183:119-130.
    PubMed     Abstract available
    
    
    February 2023
31. KAWAKAMI H, Sunakawa Y, Inoue E, Matoba R, et al
    Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
    Eur J Cancer. 2023;184:10-20.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum